Little Warrior Foundation, Inc.

Based in the US, the Little Warrior Foundation, Inc. focuses on funding innovative research and clinical trials dedicated to finding effective treatments for Ewing Sarcoma, a rare bone cancer affecting children and young adults. Little Warrior Foundation, Inc. was founded in 2020 in Brookfield, US, with a mission to support research initiatives for Ewing Sarcoma.

The foundation collaborates with various research institutions and therapeutic companies to advance the development of targeted treatments. The founder's specific history is not disclosed. The Little Warrior Foundation (LWF) primarily focuses on funding high-potential research projects and clinical trials aimed at finding effective treatments for Ewing Sarcoma, a rare and aggressive bone cancer that primarily affects children and young adults. The foundation collaborates with research institutions and therapeutic companies, such as Aptadel Therapeutics, to support the development of innovative therapies like ADEL-101, an aptamer-based drug conjugate designed for precision targeting.

Additionally, LWF is dedicated to launching new clinical trials in partnership with organizations like the Beat Childhood Cancer Foundation. These trials aim to explore promising treatments, such as DFMO, to improve outcomes for pediatric cancer patients. LWF's efforts are primarily concentrated in the United States, with potential outreach to international research communities collaborating on childhood cancer therapies, ensuring that knowledge and advancements are shared and utilized globally. The revenue model for the Little Warrior Foundation is predominantly reliant on donations and fundraising efforts from individuals, families, and community organizations.

Transactions typically occur through direct contributions to fund specific research projects and clinical trials. For instance, individual donations or corporate sponsorships may be directed towards initiatives like the USD 680,000 grant for the ADEL-101 research or the USD 700,000 grant to support multiple clinical trials with the Beat Childhood Cancer Foundation. These funds are allocated specifically for high-potential therapies and trials that directly benefit children diagnosed with Ewing Sarcoma. The foundation emphasizes that 100% of the funds raised are channeled into research, ensuring that contributions have a direct impact on advancing treatment options for affected children.